Search Results - "Galiè, N."

The role of the right ventricle in pulmonary arterial hypertension by Vonk Noordegraaf, A, Galiè, N

“…Although changes in the pulmonary vasculature are the primary cause of pulmonary arterial hypertension (PAH), severity of symptoms and survival are strongly…”
Get full text

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) by Galiè, Nazzareno, Humbert, Marc, Vachiery, Jean-Luc, Gibbs, Simon, Lang, Irene, Torbicki, Adam, Simonneau, Gérald, Peacock, Andrew, Vonk Noordegraaf, Anton, Beghetti, Maurice, Ghofrani, Ardeschir, Gomez Sanchez, Miguel Angel, Hansmann, Georg, Klepetko, Walter, Lancellotti, Patrizio, Matucci, Marco, McDonagh, Theresa, Pierard, Luc A, Trindade, Pedro T, Zompatori, Maurizio, Hoeper, Marius

Get full text

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial by Galiè, N, Prof, Rubin, LJ, Prof, Hoeper, MM, Prof, Jansa, P, MD, Al-Hiti, H, MD, Meyer, GMB, MD, Chiossi, E, Kusic-Pajic, A, MD, Simonneau, G, Prof

“…Summary Background Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO functional class [FC] III and…”
Get full text

Survival with first-line bosentan in patients with primary pulmonary hypertension by McLaughlin, V. V, Sitbon, O, Badesch, D. B, Barst, R. J, Black, C, Galie, N, Rainisio, M, Simonneau, G, Rubin, L. J

“…Primary pulmonary hypertension (PPH) is a progressive disease with high mortality. Administration of i.v. epoprostenol has demonstrated improved exercise…”
Get full text

Cardiovascular reflex tests detect autonomic dysfunction in symptomatic and pre-symptomatic subjects with hereditary transthyretin amyloidosis by Guaraldi, P., Rocchi, C., Cani, I., Gagliardi, C., Longhi, S., Baschieri, F., Rinaldi, R., Frezza, E., D’Angelo, R., Barletta, G., Calandra-Buonaura, G., Galiè, N., Massa, R., Cortelli, P.

“…Purpose Autonomic dysfunction is a distinctive but undervalued feature of hereditary transthyretin amyloidosis (ATTRv). It may predate the onset of…”
Get full text

End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? by Peacock, A. J, Naeije, R, Galie, N, Rubin, L

“…There is enormous interest in the treatment of pulmonary arterial hypertension (PAH), so it is appropriate to consider the design of trials of new therapies…”
Get full text

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 by Humbert, M, Barst, R.J, Robbins, I.M, Channick, R.N, Galie, N, Boonstra, A, Rubin, L.J, Horn, E.M, Manes, A, Simonneau, G

“…The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in…”
Get full text

Guidelines for the diagnosis and treatment of pulmonary hypertension by Galiè, N, Hoeper, M M, Humbert, M, Torbicki, A, Vachiery, J-L, Barbera, J A, Beghetti, M, Corris, P, Gaine, S, Gibbs, J S, Gomez-Sanchez, M A, Jondeau, G, Klepetko, W, Opitz, C, Peacock, A, Rubin, L, Zellweger, M, Simonneau, G

Get full text

Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed by Galiè, N, Palazzini, M, Manes, A

Get full text

The use of combination therapy in pulmonary arterial hypertension: new developments by Galie, N, Negro, L, Simonneau, G

“…* Institute of Cardiology, University of Bologna, Bologna, Italy. # Hôpital Antoine Béclère, Université Paris-Sud, Clamart, France. CORRESPONDENCE: N. Galiè,…”
Get full text

Liver toxicity of sitaxentan in pulmonary arterial hypertension by Galiè, N, Hoeper, M M, Gibbs, J S R, Simonneau, G

Get full text

Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals by Sitbon, O, Galiè, N

“…Major advances have occurred in the treatment of pulmonary arterial hypertension (PAH) over the past decade. The advent of PAH-specific pharmacological…”
Get full text

Pulmonary Vascular Resistances among Heart Transplant Candidates: Are We Looking to the Right Player? by Masetti, M., Moretta, A., Sabatino, M., Russo, A., Martin Suarez, S., Loforte, A., Galiè, N., Potena, L.

“…Pulmonary vascular resistances (PVR) are among the key measurements derived from right heart catheterization (RHC) in the prognostic assessment of patients…”
Get full text

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol by Sitbon, O, McLaughlin, V V, Badesch, D B, Barst, R J, Black, C, Galiè, N, Humbert, M, Rainisio, M, Rubin, L J, Simonneau, G

“…Background: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial…”
Get full text

Electrocardiogram analysis in Anderson-Fabry disease: a valuable tool for progressive phenotypic expression tracking by Parisi, V, Baldassarre, R, Ferrara, V, Ditaranto, R, Barlocco, F, Lillo, R, Re, F, Marchi, G, Chiti, C, Di Nicola, F, Catalano, C, Barile, L, Schiavo, M A, Ponziani, A, Saturi, G, Caponetti, A G, Berardini, A, Graziosi, M, Pasquale, F, Salamon, I, Ferracin, M, Nardi, E, Capelli, I, Girelli, D, Gimeno Blanes, J R, Biffi, M, Galiè, N, Olivotto, I, Graziani, F, Biagini, E

“…Electrocardiogram (ECG) has proven to be useful for early detection of cardiac involvement in Anderson-Fabry disease (AFD); however, little evidence is…”
Get full text

Results from the REPAIR Study Final Analysis: Effects of Macitentan on Right Ventricular (RV) Remodelling in Pulmonary Arterial Hypertension (PAH) by Noordegraaf, A. Vonk, Channick, R., Cottreel, E., Kiely, D., Martin, N., Moiseeva, O., Peacock, A., Tawakol, A., Torbicki, A., Rosenkranz, S., Galiè, N.

“…To evaluate the effect of macitentan on RV and hemodynamic properties in PAH patients. REPAIR (NCT02310672) was a 52-week, open-label, single-arm, multicentre…”
Get full text

The new clinical trials on pharmacological treatment in pulmonary arterial hypertension by Galie, N, Manes, A, Branzi, A

“…Past medical therapy for pulmonary arterial hypertension included the use of calcium-channel antagonists in acute vasoreactive subjects and oral anticoagulants…”
Get full text

Pulmonary arterial hypertension associated to connective tissue diseases by Galiè, N, Manes, A, Farahani, K V, Pelino, F, Palazzini, M, Negro, L, Romanazzi, S, Branzi, A

“…Pulmonary arterial hypertension is a well-known complication of connective tissue diseases such as systemic sclerosis, systemic lupus erythematosus, mixed…”
Get full text

Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients by Marfella, R., Paolisso, P., Sardu, C., Bergamaschi, L., D’Angelo, E.C., Barbieri, M., Rizzo, M.R., Messina, V., Maggi, P., Coppola, N., Pizzi, C., Biffi, M., Viale, P., Galié, N., Paolisso, G.

“…Tocilizumab (TCZ) is used for treating moderate-to-severe Covid-19 pneumonia by targeting interleukin-6 receptors (IL-6Rs) and reducing cytokine release. Yet,…”
Get full text

Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells by Tantini, Benedetta, Manes, Alessandra, Fiumana, Emanuela, Pignatti, Carla, Guarnieri, Carlo, Zannoli, Romano, Branzi, Angelo, Galié, Nazzareno

“…Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and by obstructive changes of the pulmonary vasculature including smooth muscle cell…”
Get full text